Global Markets Direct’s, ‘Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2015′, provides an overview of the Glioblastoma Multiforme (GBM)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 9
Glioblastoma Multiforme (GBM) Overview 10
Therapeutics Development 11
Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 13
Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 29
Glioblastoma Multiforme (GBM) - Pipeline Products Glance 33
Glioblastoma Multiforme (GBM) - Products under Development by Companies 37
Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 56
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 59
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 223
Drug Profiles 250
Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 805
Glioblastoma Multiforme (GBM) - Dormant Projects 1117
Glioblastoma Multiforme (GBM) - Discontinued Products 1128
Glioblastoma Multiforme (GBM) - Product Development Milestones 1131
Appendix 1142

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2015 46
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2015 47
Number of Products under Development by Companies, H2 2015 49
Number of Products under Development by Companies, H2 2015 (Contd..1) 50
Number of Products under Development by Companies, H2 2015 (Contd..2) 51
Number of Products under Development by Companies, H2 2015 (Contd..3) 52
Number of Products under Development by Companies, H2 2015 (Contd..4) 53
Number of Products under Development by Companies, H2 2015 (Contd..5) 54
Number of Products under Development by Companies, H2 2015 (Contd..6) 55
Number of Products under Development by Companies, H2 2015 (Contd..7) 56
Number of Products under Development by Companies, H2 2015 (Contd..8) 57
Number of Products under Development by Companies, H2 2015 (Contd..9) 58
Number of Products under Development by Companies, H2 2015 (Contd..10) 59
Number of Products under Development by Companies, H2 2015 (Contd..11) 60
Number of Products under Development by Companies, H2 2015 (Contd..12) 61
Number of Products under Development by Companies, H2 2015 (Contd..13) 62
Number of Products under Development by Companies, H2 2015 (Contd..14) 63
Number of Products under Investigation by Universities/Institutes, H2 2015 65
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 66
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 67
Comparative Analysis by Late Stage Development, H2 2015 68
Comparative Analysis by Clinical Stage Development, H2 2015 69
Comparative Analysis by Early Stage Development, H2 2015 70
Comparative Analysis by Unknown Stage Development, H2 2015 71
Products under Development by Companies, H2 2015 72
Products under Development by Companies, H2 2015 (Contd..1) 73
Products under Development by Companies, H2 2015 (Contd..2) 74
Products under Development by Companies, H2 2015 (Contd..3) 75
Products under Development by Companies, H2 2015 (Contd..4) 76
Products under Development by Companies, H2 2015 (Contd..5) 77
Products under Development by Companies, H2 2015 (Contd..6) 78
Products under Development by Companies, H2 2015 (Contd..7) 79
Products under Development by Companies, H2 2015 (Contd..8) 80
Products under Development by Companies, H2 2015 (Contd..9) 81
Products under Development by Companies, H2 2015 (Contd..10) 82
Products under Development by Companies, H2 2015 (Contd..11) 83
Products under Development by Companies, H2 2015 (Contd..12) 84
Products under Development by Companies, H2 2015 (Contd..13) 85
Products under Development by Companies, H2 2015 (Contd..14) 86
Products under Development by Companies, H2 2015 (Contd..15) 87
Products under Development by Companies, H2 2015 (Contd..16) 88
Products under Development by Companies, H2 2015 (Contd..17) 89
Products under Development by Companies, H2 2015 (Contd..18) 90
Products under Investigation by Universities/Institutes, H2 2015 91
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 92
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 93
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H2 2015 94
Glioblastoma Multiforme (GBM) - Pipeline by Actelion Ltd, H2 2015 95
Glioblastoma Multiforme (GBM) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 96
Glioblastoma Multiforme (GBM) - Pipeline by Actinogen Limited, H2 2015 97
Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2015 98
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H2 2015 99
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2015 100
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Cancer Therapeutics, H2 2015 101
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H2 2015 102
Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2015 103
Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2015 104
Glioblastoma Multiforme (GBM) - Pipeline by Ambrx, Inc., H2 2015 105
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2015 106
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 107
Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2015 108
Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2015 109
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2015 110
Glioblastoma Multiforme (GBM) - Pipeline by Argon Pharma S.L., H2 2015 111
Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2015 112
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H2 2015 113
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2015 114
Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2015 115
Glioblastoma Multiforme (GBM) - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 116
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015 117
Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc., H2 2015 118
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2015 119
Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2015 120
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H2 2015 121
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H2 2015 122
Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 123
Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H2 2015 124
Glioblastoma Multiforme (GBM) - Pipeline by Caladrius Biosciences, Inc. , H2 2015 125
Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015 126
Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2015 127
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H2 2015 128
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H2 2015 129
Glioblastoma Multiforme (GBM) - Pipeline by Cellectis S.A., H2 2015 130
Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H2 2015 131
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H2 2015 132
Glioblastoma Multiforme (GBM) - Pipeline by Champions Oncology, Inc., H2 2015 133
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H2 2015 134
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H2 2015 135
Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp., H2 2015 136
Glioblastoma Multiforme (GBM) - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015 137
Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H2 2015 138
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2015 139
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H2 2015 140
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2015 141
Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC, Inc., H2 2015 142
Glioblastoma Multiforme (GBM) - Pipeline by Delenex Therapeutics AG, H2 2015 143
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015 144
Glioblastoma Multiforme (GBM) - Pipeline by DiscoveryBiomed, Inc., H2 2015 145
Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 146
Glioblastoma Multiforme (GBM) - Pipeline by e-Therapeutics Plc, H2 2015 147
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2015 148
Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc., H2 2015 149
Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2015 150
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2015 151
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2015 152
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H2 2015 153
Glioblastoma Multiforme (GBM) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 154
Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2015 155
Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2015 156
Glioblastoma Multiforme (GBM) - Pipeline by Exelixis, Inc., H2 2015 157
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 158
Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research, Inc., H2 2015 159
Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics, Inc., H2 2015 160
Glioblastoma Multiforme (GBM) - Pipeline by Galileo Research s.r.l., H2 2015 161
Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H2 2015 162
Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co., Ltd., H2 2015 163
Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H2 2015 164
Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H2 2015 165
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2015 166
Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2015 167
Glioblastoma Multiforme (GBM) - Pipeline by HEC Pharm Co., Ltd., H2 2015 168
Glioblastoma Multiforme (GBM) - Pipeline by Hospira, Inc., H2 2015 169
Glioblastoma Multiforme (GBM) - Pipeline by immatics biotechnologies GmbH, H2 2015 170
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2015 171
Glioblastoma Multiforme (GBM) - Pipeline by Immunocore Limited, H2 2015 172
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H2 2015 173
Glioblastoma Multiforme (GBM) - Pipeline by Immunovaccine, Inc., H2 2015 174
Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 175
Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics, Inc., H2 2015 176
Glioblastoma Multiforme (GBM) - Pipeline by InteRNA Technologies B.V., H2 2015 177
Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical, Inc., H2 2015 178
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015 179
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2015 180
Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H2 2015 181
Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc., H2 2015 182
Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015 183
Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 184
Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma, Inc., H2 2015 185
Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co., Ltd., H2 2015 186
Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology, Inc., H2 2015 187
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2015 188
Glioblastoma Multiforme (GBM) - Pipeline by LinXis B.V., H2 2015 189
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 190
Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2015 191
Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2015 192
Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc, H2 2015 193
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune, LLC, H2 2015 194
Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2015 195
Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 196
Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc., H2 2015 197
Glioblastoma Multiforme (GBM) - Pipeline by Nascent Biotech, Inc., H2 2015 198
Glioblastoma Multiforme (GBM) - Pipeline by Nemucore Medical Innovations, Inc., H2 2015 199
Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015 200
Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem, Inc., H2 2015 201
Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corporation, H2 2015 202
Glioblastoma Multiforme (GBM) - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2015 203
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H2 2015 204
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2015 205
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H2 2015 206
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2015 207
Glioblastoma Multiforme (GBM) - Pipeline by Omniox, Inc., H2 2015 208
Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics, Inc., H2 2015 209
Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2015 210
Glioblastoma Multiforme (GBM) - Pipeline by Oncolytics Biotech Inc., H2 2015 211
Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics, Inc., H2 2015 212
Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 213
Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 214
Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H2 2015 215
Glioblastoma Multiforme (GBM) - Pipeline by OXiGENE, Inc., H2 2015 216
Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H2 2015 217
Glioblastoma Multiforme (GBM) - Pipeline by Panacela Labs, Inc., H2 2015 218
Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics, Inc., H2 2015 219
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 220
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2015 221
Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine, Inc., H2 2015 222
Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech, Inc., H2 2015 223
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H2 2015 224
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H2 2015 225
Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 226
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H2 2015 227
Glioblastoma Multiforme (GBM) - Pipeline by RestorGenex Corporation, H2 2015 228
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 229
Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2015 230
Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H2 2015 231
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2015 232
Glioblastoma Multiforme (GBM) - Pipeline by Selvita SA, H2 2015 233
Glioblastoma Multiforme (GBM) - Pipeline by Siena Biotech S.p.A., H2 2015 234
Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau S.p.A., H2 2015 235
Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H2 2015 236
Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics, Inc., H2 2015 237
Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 238
Glioblastoma Multiforme (GBM) - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015 239
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2015 240
Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 241
Glioblastoma Multiforme (GBM) - Pipeline by Sun Pharmaceutical Industries Limited, H2 2015 242
Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences, Inc., H2 2015 243
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H2 2015 244
Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co. KG, H2 2015 245
Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2015 246
Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 247
Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2015 248
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 249
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H2 2015 250
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 251
Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2015 252
Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc., H2 2015 253
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 254
Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2015 255
Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2015 256
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H2 2015 257
Assessment by Monotherapy Products, H2 2015 258
Assessment by Combination Products, H2 2015 259
Number of Products by Stage and Target, H2 2015 261
Number of Products by Stage and Mechanism of Action, H2 2015 273
Number of Products by Stage and Route of Administration, H2 2015 282
Number of Products by Stage and Molecule Type, H2 2015 284
Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H2 2015 839
Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2015 1151
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2015 1152
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2015 1153
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2015 1154
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2015 1155
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2015 1156
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2015 1157
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2015 1158
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2015 1159
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2015 1160
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2015 1161
Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2015 1162
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2015 1163
Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2015 1164

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2015 46
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2015 47
Number of Products under Development by Companies, H2 2015 48
Number of Products under Investigation by Universities/Institutes, H2 2015 64
Comparative Analysis by Late Stage Development, H2 2015 68
Comparative Analysis by Clinical Stage Development, H2 2015 69
Comparative Analysis by Early Stage Products, H2 2015 70
Assessment by Monotherapy Products, H2 2015 258
Assessment by Combination Products, H2 2015 259
Number of Products by Top 10 Targets, H2 2015 260
Number of Products by Stage and Top 10 Targets, H2 2015 260
Number of Products by Top 10 Mechanism of Actions, H2 2015 272
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 272
Number of Products by Top 10 Routes of Administration, H2 2015 281
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 281
Number of Products by Top 10 Molecule Types, H2 2015 283
Number of Products by Stage and Top 10 Molecule Types, H2 2015 283